@icepharma1 @jfais20 Lump sum or amortized (and I agree, likely to be paid over time), at such a high cost, patients and payors are likely to opt for the best. $BRMN ‘s Phase 1/2 data reported today leave room for differentiation in durability, FVIII levels and ABR’s with the $PFE / $SGMO option.